Diligence memo · auto-generated · as of July 3, 2026

BioTrace Medical, Inc.

BioTrace Medical, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

BioTrace Medical, Inc. operates in Healthtech, based in MENLO PARK.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

BioTrace Medical, Inc. has raised $22M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $11M on 2021-03-01.

Most recent recorded round closed around 2021-03-01.

Valuation (modeled)modeled

Provath models BioTrace Medical, Inc. at approximately $191M (range $14M–$891M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.63× the median modeled value of Series A Healthtech companies in 2019–2021 (124 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 28 months.

Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.9× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 81% of Healthtech peers (2138 compared).

Modeled value ranks above 86% of those peers.

Closest niche peers: Itamar Medical Ltd., ChartSpan Medical Technologies, Inc., 4G Clinical, LLC, Wellness Group Investors, LLC, Avation Medical, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.